Jacopo Giuliani

Summary

Country: Italy

Publications

  1. doi request reprint [Oncological quality indicators and Colorectal Cancer Program: data from 2009-2010 of University Hospital in Ferrara, Italy]
    Jacopo Giuliani
    Unità Operativa Oncologia, Azienda Ospedaliero Universitaria, Ferrara
    Recenti Prog Med 103:56-61. 2012
  2. doi request reprint The Occurrence of Gastrointestinal Stromal Tumors and Second Malignancies
    Jacopo Giuliani
    Department of Oncology, Mater Salutis Hospital, ASL 21 della Regione Veneto, Via Gianella 1 37045, Legnago, VR, Italy
    J Gastrointest Cancer 46:408-12. 2015
  3. doi request reprint The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?
    Jacopo Giuliani
    Palliative Care Unit, Mater Salutis Hospital, Legnago VR, Italy
    Cutan Ocul Toxicol 32:248-51. 2013
  4. doi request reprint Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?
    Jacopo Giuliani
    Palliative Care Unit, Mater Salutis Hospital, Italy
    Arch Dermatol Res 305:653-8. 2013
  5. doi request reprint Immunotherapy and targeted therapies in metastatic renal cell carcinoma: is there a preferred sequence?
    Jacopo Giuliani
    Clinical Oncology Unit, St Anna University Hospital, Ferrara, Italy
    Cancer Biother Radiopharm 27:513-8. 2012
  6. doi request reprint Skin rash during cetuximab treatment in advanced colorectal cancer: is age a clinical predictor?
    Jacopo Giuliani
    Palliative Care Unit, Mater Salutis Hospital, ULSS 21, Via Gianella 1, 37045 Legnago, Verona, Italy
    J Gastrointest Cancer 44:241-5. 2013
  7. doi request reprint Gastrointestinal stromal tumors and other malignancies: a case series
    Jacopo Giuliani
    Clinical Oncology Unit, St Anna University Hospital, Ferrara, Italy
    J Gastrointest Cancer 43:634-7. 2012
  8. doi request reprint The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: how much does it cost? A retrospecive economic assessment from a single-center experience
    Jacopo Giuliani
    Clinical Oncology Unit, St Anna University Hospital, Ferrara, Italy
    Tumori 98:408-12. 2012
  9. doi request reprint Ovarian cancer in elderly patients: a difference in treatment based on age?
    Jacopo Giuliani
    Clinical Oncology Unit, St Anna University Hospital, C so Giovecca 203, 44100, Ferrara, Italy
    Arch Gynecol Obstet 286:1545-8. 2012
  10. doi request reprint Ampulla of Vater carcinoma in real-world clinical practice: a case series
    Jacopo Giuliani
    Department of Oncology, Mater Salutis Hospital, ASL 21 della Regione Veneto, Legnago Verona Italy
    Tumori 101:e75-8. 2015

Detail Information

Publications14

  1. doi request reprint [Oncological quality indicators and Colorectal Cancer Program: data from 2009-2010 of University Hospital in Ferrara, Italy]
    Jacopo Giuliani
    Unità Operativa Oncologia, Azienda Ospedaliero Universitaria, Ferrara
    Recenti Prog Med 103:56-61. 2012
    ..On the basis of our experience, we concluded for high-quality care for both population. Any critical point should be carefully analysed in order to implement quality of care...
  2. doi request reprint The Occurrence of Gastrointestinal Stromal Tumors and Second Malignancies
    Jacopo Giuliani
    Department of Oncology, Mater Salutis Hospital, ASL 21 della Regione Veneto, Via Gianella 1 37045, Legnago, VR, Italy
    J Gastrointest Cancer 46:408-12. 2015
    ..In the absence of definitive data, it could be interesting to compare the frequency of the occurrence of GIST and second malignancies in literature...
  3. doi request reprint The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?
    Jacopo Giuliani
    Palliative Care Unit, Mater Salutis Hospital, Legnago VR, Italy
    Cutan Ocul Toxicol 32:248-51. 2013
    ..No studies like the above have been published until now...
  4. doi request reprint Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?
    Jacopo Giuliani
    Palliative Care Unit, Mater Salutis Hospital, Italy
    Arch Dermatol Res 305:653-8. 2013
    ..765). In conclusion, we can affirm that age is an insufficient predictor of acneiform skin rash during erlotinib treatment in advanced NSCLC and does not seem to statistically influence the appearance, duration and grade of skin rash...
  5. doi request reprint Immunotherapy and targeted therapies in metastatic renal cell carcinoma: is there a preferred sequence?
    Jacopo Giuliani
    Clinical Oncology Unit, St Anna University Hospital, Ferrara, Italy
    Cancer Biother Radiopharm 27:513-8. 2012
    ..The aim of this study was to evaluate the outcome of target therapies on clinical practice after the era of cytokine-based therapy in mRCC...
  6. doi request reprint Skin rash during cetuximab treatment in advanced colorectal cancer: is age a clinical predictor?
    Jacopo Giuliani
    Palliative Care Unit, Mater Salutis Hospital, ULSS 21, Via Gianella 1, 37045 Legnago, Verona, Italy
    J Gastrointest Cancer 44:241-5. 2013
    ..The aim of this study is to evaluate the intensity and the duration of skin rash in young and elderly patients treated with cetuximab for advanced colorectal cancer, in order to define a possible relationship between age and skin toxicity...
  7. doi request reprint Gastrointestinal stromal tumors and other malignancies: a case series
    Jacopo Giuliani
    Clinical Oncology Unit, St Anna University Hospital, Ferrara, Italy
    J Gastrointest Cancer 43:634-7. 2012
    ..This paper aims to review the clinical and pathological features of gastrointestinal stromal tumors (GISTs) occurring with other malignancies...
  8. doi request reprint The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: how much does it cost? A retrospecive economic assessment from a single-center experience
    Jacopo Giuliani
    Clinical Oncology Unit, St Anna University Hospital, Ferrara, Italy
    Tumori 98:408-12. 2012
    ..The aim of this study is to estimate the costs for the foreseeable management of skin toxicity in patients treated with cetuximab in our institute in order to assess the direct medical economic impact...
  9. doi request reprint Ovarian cancer in elderly patients: a difference in treatment based on age?
    Jacopo Giuliani
    Clinical Oncology Unit, St Anna University Hospital, C so Giovecca 203, 44100, Ferrara, Italy
    Arch Gynecol Obstet 286:1545-8. 2012
    ..The aim of this study was to examine if treatment strategies differ by age in the elderly population with ovarian cancer in daily clinical practice...
  10. doi request reprint Ampulla of Vater carcinoma in real-world clinical practice: a case series
    Jacopo Giuliani
    Department of Oncology, Mater Salutis Hospital, ASL 21 della Regione Veneto, Legnago Verona Italy
    Tumori 101:e75-8. 2015
    ..The aim of this report was to describe the way in which a rare and niche disease like ampulla of Vater carcinoma (AVC) was treated in real-world clinical practice...
  11. ncbi request reprint Targeted agents and oxaliplatin-containing regimens for the treatment of colon cancer
    Andrea Bonetti
    Department of Oncology, ASL 21 della Regione Veneto, Via Gianella 1 37045 Legnago Verona, Italy
    Anticancer Res 34:423-34. 2014
    ..However, positive selection criteria for targeted agents have not been identified. The results of oxaliplatin-containing regimens are critically presented and discussed in this review. ..
  12. doi request reprint The pharmacological costs of complete liver resections in unselected advanced colorectal cancer patients: a review of published Phase II and III trials
    Jacopo Giuliani
    Mater Salutis Hospital AULSS 21 della Regione Veneto Medical Oncology, Legnago VR, Italy
    Expert Rev Pharmacoecon Outcomes Res 15:101-10. 2015
    ..The range of activity is greatly amplified when the costs are compared. ..
  13. doi request reprint Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question
    Jacopo Giuliani
    Department of Oncology, Mater Salutis Hospital, ASL 21 della Regione Veneto, Legnago Verona Italy
    Tumori 101:e115-7. 2015
    ..The peculiarities of our case are the site of the metastatic disease and the complete lack of a response to gefitinib in a patient with an activating mutation in EGFR exon 21. ..
  14. doi request reprint Trends in survival for patients with metastatic breast cancer: is survival improving?
    Jacopo Giuliani
    Department of Oncology, Mater Salutis Hospital, ASL 21 della Regione Veneto, Legnago Verona Italy
    Tumori 101:347-52. 2015
    ..The aim of this outcome study was to evaluate the most reliable parameters to define the long-term result in terms of OS of different treatment strategies for mBC patients in a real-world clinical practice...